OXFORD ANNOUNCES RESULTS OF TROVAX STUDY

Oxford Biomedica has reported that initial analyses of Phase II trial results suggest that its lead oncology product, TroVax, improves survival in patients with metastatic colorectal cancer.

TroVax induces an immune response against the tumor antigen 5T4, which is broadly distributed throughout a wide range of solid tumors. The product consists of a pox virus (MVA) gene-transfer system, which delivers the gene for 5T4.